ArticleFrontiers in oncology2026
Clinical efficacy of Atezolizumab/Bevacizumab combined with TACE in treating BCLC stage C hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of advanced primary liver cancer [Barcelona Clinic Liver Cancer (BCLC) stage C] remains poor. Although atezolizumab plus bevacizumab (Ate/Bev) is a standard treatment, the potential of intensifying this regimen into a triple therapy by adding local intervention is unclear. Aim: To evaluate the efficacy of Ate/Bev plus transarterial chemoembolisation (TACE) in the treatment of BCLC stage C advanced hepatocellular carcinoma (HCC). Methods: The clinical data of 25 patients with BCLC-C HCC treated with Ate/Bev plus TACE at Guangdong Provincial Traditional Chinese Medicine Hospital between January 2022 and October 2024 were retrospectively analyzed. Efficacy was evaluated using Response Evaluation Criteria in Solid Tumors version 1.1, with follow-up until April 2025. The primary endpoints included the objective response rate, disease control rate, progression-free survival (PFS), and safety. Results: Of the 33 patients with intermediate-/advanced-stage HCC receiving the triple therapy, 25 were categorized as BCLC stage C HCC. Twelve patients died, and thirteen survived, during follow-up. The objective response rate was 32%, PFS was 7.960 ± 6.624 months, and overall survival (OS) was 12.880 ± 7.769 months. OS and PFS significantly differed by the neutrophil-to-lymphocyte ratio (≥ 3 vs < 3). The hazard ratios for median PFS and median OS were significantly different (P < 0.005) between the two groups, at 2.004 (95% confidence interval: 1.86-3.74) and 1.765 (95% confidence interval: 1.24-3.06), respectively. The incidence of all-grade adverse reactions was 100%, with grade 3/4 events seen in 4% of patients. No treatment-related deaths occurred. Conclusion: Atezolizumab combined with bevacizumab and TACE may be safe and effective in the treatment of BCLC stage C hepatocellular carcinoma. Baseline NLR may be an important potential biomarker for predicting the efficacy and prognosis of such patients. However, the above conclusions still need to be further verified by large-sample prospective randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.